Search

Displaying results 4701 - 4710 of 6076 in total
  1. Drug

    Pegsitacianine

    go.drugbank.com/drugs/DB19098
    Investigational

    under investigation in clinical trial NCT05576974 (A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for

  2. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  3. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  4. Drug

    Elacridar

    go.drugbank.com/drugs/DB04881
    Investigational

    Elacridar (GW120918) is an oral bioenhancer that targets multiple drug resistance in tumors. In many cases, the appearance of multidrug resistance in cancer is due to a change in expression of protein inhibitors. As of August 2007 elacri...

  5. Drug

    R673

    go.drugbank.com/drugs/DB05466
    Experimental

    The phase II program for treatment of depression and anxiety is ongoing in the US and EU.It is not clear how tachykinin antagonists exert their effect, but SP levels have been commonly linked to the functioning

  6. Drug

    rhMBL

    go.drugbank.com/drugs/DB05237
    Investigational

    rhMBL is a protein therapeutic being developed by Enzon for the prevention and treatment of severe infections in individuals with low levels of Mannose-Binding Lectin (MBL).

  7. Drug

    Motavizumab

    go.drugbank.com/drugs/DB06310
    Investigational

    Categories: Antiinfectives for Systemic Use
  8. Drug

    PI-0824

    go.drugbank.com/drugs/DB05516
    Investigational

    Peptimmune, Inc. has developed a new therapy for the treatment of PV, PI-0824. … It is hoped that use of PI-0824 will reduce or potentially eliminate the need for high dose steroids and drugs that suppress the immune system.

  9. Drug

    TM30339

    go.drugbank.com/drugs/DB05085
    Experimental

    TM30339 is developed for the treatment of obesity.

  10. Drug

    ND7001

    go.drugbank.com/drugs/DB05142
    Experimental

    ND7001, a selective PDE2 inhibitor is in clinical trials for the treatment of depression. ND7001 is a solid.